Phibro(US:PAHC)2024-11-08 16:08Financial Performance - Q1 FY2025 (Consolidated) - Net sales increased by 13% to $260.4 million compared to $231.3 million in Q1 FY24[10] - Adjusted EBITDA increased by 64% to $30.7 million compared to $18.7 million in Q1 FY24[10] - Adjusted net income increased by 155% to $14.1 million compared to $5.5 million in Q1 FY24[10] - Adjusted diluted EPS increased by 154% to $0.35 compared to $0.14 in Q1 FY24[10] Financial Performance - Q1 FY2025 (Animal Health) - Animal Health net sales increased by 14% to $182.5 million[12] - MFAs & other sales increased by 15%[12] - Vaccines sales increased by 22%[12] - Nutritional specialties sales increased by 6%[12] - Animal Health adjusted EBITDA increased by 42% to $40.4 million[12] - Animal Health adjusted EBITDA margin increased by 440 bps to 22.1%[12] Financial Performance - Q1 FY2025 (Other Segments) - Performance Products net sales increased by 27% to $18.8 million[14] - Mineral Nutrition net sales increased by 5% to $59.1 million[14] FY2025 Guidance (Phibro Standalone) - Net sales are projected to be between $1.050 billion and $1.100 billion[8] - Adjusted EBITDA is projected to be between $124 million and $132 million[8] - Adjusted EPS is projected to be between $1.34 and $1.48[8]